Skip to main content

Table 1 Cardiac function analysis with echocardiography

From: SDF-1α upregulation by atorvastatin in rats with acute myocardial infarction via nitric oxide production confers anti-inflammatory and anti-apoptotic effects

Groups S B A AL AA
Before AMI
LVEF(%) 70.52±2.09 69.27±2.33 68.75±3.01 70.11±2.67 69.35±2.82
FS(%) 35.98±3.15 34.83±4.02 37.09±3.73 36.62±4.09 35.26±3.35
LVVs(ml) 2.03±0.27 1.99±0.35 2.16±0.31 2.08±0.30 2.05±0.28
LVVd(ml) 5.76±0.30 5.97±0.38 5.85±0.41 5.81±0.34 5.85±0.31
CO(ml) 3.72±0.18 3.98±0.27 3.69±0.22 3.73±0.21 3.81±0.25
HR(bpm) 454±68 462±59 455±61 466±78 459±71
One day after AMI
LVEF(%) 69.51±1.94 46.13±2.61* 45.26±2.44* 46.09±2.72* 45.68±2.59*
FS(%) 35.78±3.23 25.71±3.06* 26.07±2.99* 25.22±3.30* 24.97±3.26*
LVVs(ml) 2.08±0.31 3.52±0.31* 3.47±0.36* 3.56±0.29* 3.45±0.30*
LVVd(ml) 5.82±0.27 6.49±0.37* 6.71±0.35* 6.55±0.42* 6.61±0.39*
CO(ml) 3.74±0.19 2.97±0.22* 3.24±0.27* 2.99±0.24* 3.16±0.25*
HR(bpm) 461±70 536±67 551±56 549±62 541±71
Seven days after AMI
LVEF(%) 70.07±2.11 44.91±2.72* 55.57±3.61*# 49.98±3.03*#$ 48.98±2.87*#$
FS(%) 36.09±3.12 23.96±3.41* 32.58±3.35# 27.20±3.27*#$ 27.86±3.32*#$
LVVs(ml) 2.04±0.25 3.63±0.37* 2.71±0.53*# 3.11±0.46*# 3.18±0.41*#
LVVd(ml) 5.67±0.23 6.53±0.29* 6.03±0.28*# 6.26±0.24* 6.41±0.26*$
CO(ml) 3.63±0.21 2.90±0.24* 3.32±0.31 3.09±0.26* 3.23±0.29*#$
HR(bpm) 457±63 547±66 488±57 517±68 522±63
  1. · * P<0.05 vs. Sham group.
  2. · # P<0.05 vs. Blank Control group.
  3. · $ P<0.05 vs. Atorvastatin group.
  4. · S=Sham operated group; B=Blank control group; A=Atorvastatin group; AL=Atorvastatin+L-NAME group; AA=Atorvastatin+AMD3100 group.